For research use only. Not for therapeutic Use.
FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29)[1]. FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC50 of 18.6 nM[2].
The FASN inhibitor, FASN-IN-4 tosylate inhibits SARS-CoV-2 replication, and has the potential for COVID-19 research[2].
| Catalog Number | I046362 |
| CAS Number | 2095432-57-6 |
| Synonyms | 4-cyclopropyl-9-(4-quinolin-7-ylphenyl)sulfonyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one;4-methylbenzenesulfonic acid |
| Molecular Formula | C33H35N3O7S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H27N3O4S.C7H8O3S/c30-25-17-33-26(18-29(25)22-7-8-22)11-14-28(15-12-26)34(31,32)23-9-5-19(6-10-23)21-4-3-20-2-1-13-27-24(20)16-21;1-6-2-4-7(5-3-6)11(8,9)10/h1-6,9-10,13,16,22H,7-8,11-12,14-15,17-18H2;2-5H,1H3,(H,8,9,10) |
| InChIKey | KCCMVJUNHJQOGU-UHFFFAOYSA-N |
| SMILES | CC1=CC=C(C=C1)S(=O)(=O)O.C1CC1N2CC3(CCN(CC3)S(=O)(=O)C4=CC=C(C=C4)C5=CC6=C(C=CC=N6)C=C5)OCC2=O |
| Reference | [1]. Nicholas D. Adams, et al. Fatty acid synthase inhibitors. WO2012064642A1. [2]. Junjun Chu, et al. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. Nat Metab. 2021 Nov;3(11):1466-1475. |
